Enterprise Europe Network

French company offers connected oral drug delivery device with remote-care software for follow-up of patients at home

Country of origin:
Country: 
FRANCE
Opportunity:
External Id: 
TOFR20190919001
Published
25/09/2019
Last update
30/09/2019
Expiration date
30/09/2020

Keywords

Partner keyword: 
Computer Software
Internet Technologies/Communication (Wireless, Bluetooth)
Applications for Health
Clinical Research, Trials
Health information management
Drug delivery and other equipment
Hospital and other institutional management
Computer-aided diagnosis and therapy
Other medical/health related (not elsewhere classified)
Safety for the elderly
Other information technology and computer service activities
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
French e-Health company offers a global solution gathering a connected oral drug delivery device and a remote-care software for the follow-up of patients at home. The solution monitors and delivers at home oral drugs in a secure way and is associated with a remote-care software allowing to share data and patient-reported outcomes with healthcare professionnals. The company is seeking technical cooperations or commercial agreements with other SMEs, healthcare institutions or pharma companies.

Description

Description: 

To meet the challenge of the increase of chronic diseases, the increase of elderly patient population and the sustainability of the healthcare system, it appears that ambulatory/home cares development and oral drugs administration at home for the treatment and the management of serious diseases are the major orientation of healthcare system worldwide.
In this situation, patient and healthcare professionnals (hospital sector and ambulatory sector) need an efficient information system for an optimal organisation of cares and for an appropriate patients follow-up, checking adherence to the treatment and early alerting of adverse events or complications. In addition, oral drugs for treating serious diseases are more and more available for prescriptions by healthcare professionnals. These oral drugs are complex in terms of scheme of administration and need a close monitoring for adverse event prevention or management.
To cover this need and meet such evolution, the development is on-going for a patient-centric digital solution integrating a connected device. This solution monitors and delivers at home oral drugs in a secure way. It is associated with a remote-care software which shares clinical data, biological data, treatment data and patient-reported outcomes between all healthcare professionnals and the patient.
The application of the offer could be tailored for any diseases treated with oral drugs in at risk patients population who need scrutiny.
At the moment, experiments are led in oncology in 2 centers in France and in nephrology in renal failure in one care-network in France. The patient-centered approaches applied to the development of the remote-care software are positive for the patients and are communicated in a poster during a conference in psycho-oncology in November 2019.
The offer is adaptable: it could be the connected device alone associated with a remote-care software developed by a partner or our remote-care software alone for the digital coordination of cares and patients reported outcomes (treatment adherence included) or both of them.

The partnership could be with:
- healthcare institutions which have the project to implement digital organisation of cares,
- others SMEs which want to integrate remote-care sofware technologie or connected device with their apps to monitor adherence to drug and surveillance of patients,
- pharma companies in the frame of their randomized clinical trials or of their study in real life conditions.

The company is interested in technical cooperation agreement, research cooperation agreement or commercial agreement with technical assistance.

Advantages & innovations

Cooperation plus value: 
The offered digital and connected solutions meet these unmet needs and trends. Advantages of such digital and connected solutions : - interoperable with the healthcare network and with any connected devices, - tailored to any diseases which necessitate treatment with oral drug with real time dose adjustment in a secure way, - it would impact on the organisation of healthcare system hospital and ambulatory care, - it would bring relevance of care with a better allocation of healthcare resources utilisation for the most demanding patients population, - it would bring quality of care by preventing / mitigating adverse events or complications, - it would bring equity in terms of access of care, - it would improve outcomes and quality of life of patients and helpers, - it would improve adherence to the treatment, enhance security, limit the wastage of expensive oral drugs and reduce costs of care, - it would avoid non-relevant sanitary transportation and sparing costs/time associated.

Stage of development

Cooperation stage dev stage: 
Available for demonstration

Partner sought

Cooperation area: 
The company is looking for partners to implement the proposed digital and connected solutions in response to unmet needs. The partnership could have the objective to generate more evidence to demonstrate the value of the solution by extension to others diseases and others patients population of interest. Three types of partners can be sought : - healthcare institutions (hospitals, care-network, public, private, associations) which has the project to implement digital organisation of cares, - others SMEs which want to integrate remote-care sofware technologie or connected device with their apps to monitor adherence to drug and surveillance of patients, - pharma companies in the frame of their Randomized Clinical Trials in R&D, or of early access for drugs (ATU) or of their study in real life conditions.

Type and size

Cooperation task: 
SME 11-50,R&D Institution,SME <10,251-500,SME 51-250